Result of Annual Meeting

    RNS Number : 7393B
  Research Pharmaceutical SRV, Inc
  20 August 2008
   

    ReSearch Pharmaceutical Services, Inc.
    Results of Annual Meeting

    ReSearch Pharmaceutical Services, Inc.("RPS" or the "Company"), a leading provider of integrated clinical development outsourcing
solutions to the bio-pharmaceutical industry, is pleased to announce the results of its Annual Meeting held at its corporate headquarters
earlier today Wednesday August 20, 2008.

    The Board is pleased to announce that all resolutions relating to the common stock were approved by stockholders at the Annual Meeting. 
The sole resolution relating to the warrants was not approved by the warrant holders at the Annual Meeting. 

    Resolution 1 passed, ratifying the election of three Class I directors to our Board.  Jim Macdonald, Thomas Armstrong and Stephen
Stonefield were elected to the board unanimously and are due for re-election at our annual meeting in 2011.

    Resolution 2 passed, approving the cancellation of the common stock of RPS from trading on AIM by no later than December 31, 2008.

    Resolution 3 passed, approving the reverse split of the common stock of RPS within a range of one-for-two to one-for-four.

    Resolution 4 passed, approving the RPS 2007 Equity Incentive Plan.

    Resolution 5 passed, approving the appointment of Ernst & Young, LLP as the independent auditors of RPS for the 2008 fiscal year.

    Resolution 2W was not passed by the warrant holders in relation to the cancellation of the warrants of RPS from trading on AIM.

    The Company has previously stated that it intends to cancel its common stock from trading on AIM on September 1, 2008, at which time our
nominated adviser has indicated that it would resign.  As a result, the warrants would be suspended from trading on AIM on that date, and if
the Company does not appoint another nominated advisor within one month after the suspension of the warrants from trading on AIM (which
appointment of a new nominated advisor the Company believes is unlikely), the admission of the warrants to trading on AIM would be cancelled
on October 2, 2008.

    The Company may choose to delay cancelling the common stock from trading on AIM, and if it does not cancel the common stock from trading
on AIM on September 1, 2008, the Company will request an extension of the date of cancellation from AIM and publicly announce the new date
of cancellation at least 10 business days prior to the new intended date of cancellation. In any event, the Company will not effect the
cancellation of its common stock from trading on AIM on a date later than December 31, 2008 without obtaining an additional approval from
stockholders.  The Company reserves the right to forego cancelling its common stock from trading on AIM if the Board determines that
remaining admitted to trading on AIM is in the best interests of stockholders and warrant holders.  If the date of the cancellation of the
common stock is delayed beyond September 1, 2008, the warrants will remain admitted to trading on AIM. At the time the common stock's
admission to trading on AIM is cancelled the Company's nominated adviser has indicated that it will resign and therefore the warrants will be suspended and, if within one month the Company has not
appointed another nominated adviser (which appointment of a new nominated advisor the Company believes is unlikely), the admission of the
warrants to trading on AIM will be cancelled.

    Full details of the resolutions were set out in the Notice of Annual Meeting sent to stockholders and warrant holders, is also available
on the Company's website www.rpsweb.com, dated August 1, 2008.  Resolutions 1, 3, 4 and 5 were ordinary resolutions, requiring more than 50%
of shareholders' votes to be cast for the resolutions.  Resolutions 2 and 2W were special resolutions, each requiring at least 75% of
stockholders' and warrant holders' votes, respectively, to be cast for the resolutions.

    For further information please contact:
 ReSearch Pharmaceutical Services, Inc.:  [phone]
 Daniel M. Perlman, Chairman & Chief
 Executive Officer
 Steven Bell, Chief Financial Officer

 Nominated Adviser and UK Broker:         [phone]
 Arbuthnot Securities Limited
 James Steel/Richard Tulloch


This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
RAGEADPEALNPEFE